Controlled removal of a nonviral episomal vector from transfected cells

Gene

Volumn 466, Issue 1-2, 2010, Pages 36-42

  Rupprecht, Sina ^a   Hagedorn, Claudia ^a   Seruggia, Davide ^a   Magnusson, Terese ^b   Wagner, Ernst ^b   Ogris, Manfred ^b   Lipps, Hans J ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Episomal vector; Gene therapy; Inducible expression; Mitotic stability

Indexed keywords

DOXYCYCLINE; VIRUS VECTOR; DOXIFLURIDINE; FLOXURIDINE;

ADOLESCENT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; GENE REPLICATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; SOMATIC CELL; STEM CELL; TRANSCRIPTION REGULATION; TRANSGENE; ANIMAL; BAGG ALBINO MOUSE; GENE THERAPY; GENE VECTOR; MATRIX ATTACHMENT REGION; PLASMID;

ANIMALS; FEMALE; FLOXURIDINE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; MATRIX ATTACHMENT REGIONS; MICE; MICE, INBRED BALB C; PLASMIDS; TRANSFECTION; GENETIC THERAPY;

MAMMALIA;

EID: 77956228956     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gene.2010.07.001     Document Type: Article

References (28)

1. Baiker A., et al. Mitotic stability of an episomal vector containing a human scaffold/matrix-attached region is provided by association with nuclear matrix. Nat. Cell Biol. 2000, 2:182-184.
2. Barde I., et al. Efficient control of gene expression in the hematopoietic system using a single Tet-on inducible lentiviral vector. Mol. Ther. 2006, 13:382-390.
3. Brambrink T., et al. Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell 2008, 2:151-159.
4. Giannakopoulos A., Stavrou E.F., Zarkadis I., Zoumbos N., Thrasher A.J., Athanassiadou A. The functional role of S/MARs in episomal vectors as defined by the stress-induced destabilization profile of the vector sequences. J. Mol. Biol. 2009, 387:1239-1249.
5. Gill D.R., Pringle I.A., Hyde S.C. Progress and prospects: the design and production of plasmid vectors. Gene Ther. 2009, 16:165-171.
6. Gossen M., Freundlieb S., Bender G., Muller G., Hillen W., Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995, 268:1766-1769.
7. Goverdhana S., et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol. Ther. 2005, 12:189-211.
8. Hagedorn C., Lipps H.J., Rupprecht S. The epigenetic regulation of autonomous replicons. BioMol. Concepts 2010, 1:17-30.
9. Hasan M.T., Schonig K., Berger S., Graewe W., Bujard H. Long-term, noninvasive imaging of regulated gene expression in living mice. Genesis 2001, 29:116-122.
10. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 1967, 26:365-369.
11. Jackson D.A., Juranek S., Lipps H.J. Designing nonviral vectors for efficient gene transfer and long-term gene expression. Mol. Ther. 2006, 14:613-626.
12. Jenke A.C., Rupprecht S. Non viral episomes for therapeutic interventions-where to go?. Res. Adv. Antimicrob. Agents Chemother 2010.
13. Jenke A.C., et al. Nuclear scaffold/matrix attached region modules linked to a transcription unit are sufficient for replication and maintenance of a mammalian episome. Proc. Natl Acad. Sci. USA 2004, 101:11322-11327.
14. Jiang L., et al. Tight regulation from a single Tet-off rAAV vector as demonstrated by flow cytometry and quantitative, real-time PCR. Gene Ther. 2004, 11:1057-1067.
15. Loebinger M.R., Eddaoudi A., Davies D., Janes S.M. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009, 69:4134-4142.
16. Manzini S., et al. Genetically modified pigs produced with a nonviral episomal vector. Proc. Natl Acad. Sci. USA 2006, 103:17672-17677.
17. Nguyen M., et al. Rapamycin-regulated control of antiangiogenic tumor therapy following rAAV-mediated gene transfer. Mol. Ther. 2007, 15:912-920.
18. Papapetrou E.P., Ziros P.G., Micheva I.D., Zoumbos N.C., Athanassiadou A. Gene transfer into human hematopoietic progenitor cells with an episomal vector carrying an S/MAR element. Gene Ther. 2006, 13:40-51.
19. Paulus W., Baur I., Keyvani K., Senner V. Variability of transcriptional regulation after gene transfer with the retroviral tetracycline system. J. Biotechnol. 2000, 81:159-165.
20. Piechaczek C., Fetzer C., Baiker A., Bode J., Lipps H.J. A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells. Nucleic Acids Res. 1999, 27:426-428.
21. Schaarschmidt D., Baltin J., Stehle I.M., Lipps H.J., Knippers R. An episomal mammalian replicon: sequence-independent binding of the origin recognition complex. EMBO J. 2004, 23:191-201.
22. Stehle I.M., Scinteie M.F., Baiker A., Jenke A.C., Lipps H.J. Exploiting a minimal system to study the epigenetic control of DNA replication: the interplay between transcription and replication. Chromosome Res. 2003, 11:413-421.
23. Stehle I.M., Postberg J., Rupprecht S., Cremer T., Jackson D.A., Lipps H.J. Establishment and mitotic stability of an extra-chromosomal mammalian replicon. BMC Cell Biol. 2007, 8:33.
24. Stieger K., Belbellaa B., Le Guiner C., Moullier P., Rolling F. In vivo gene regulation using tetracycline-regulatable systems. Adv. Drug Deliv. Rev. 2009, 61:527-541.
25. Suda T., Gao X., Stolz D.B., Liu D. Structural impact of hydrodynamic injection on mouse liver. Gene Ther. 2007, 14:129-137.
26. Urlinger S., Baron U., Thellmann M., Hasan M.T., Bujard H., Hillen W. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc. Natl Acad. Sci. USA 2000, 97:7963-7968.
27. Xiong W., et al. Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J. Virol. 2006, 80:27-37.
28. Xu Z.L., Mizuguchi H., Mayumi T., Hayakawa T. Regulated gene expression from adenovirus vectors: a systematic comparison of various inducible systems. Gene 2003, 309:145-151.